Starling Oncology Inc. Director Brad Hively Will Not Seek Re-election

What Happened Starling Oncology, Inc. filed an 8‑K on September 2, 2026 reporting that on September 1, 2026 director Brad Hively notified the company he will not stand for re‑election to the Board at the 2027 annual meeting of stockholders. Mr. Hively is expected to remain a director until the 2027 annual meeting, but effective immediately he will no longer serve as Vice Chairman of the Board or as a member of the Compliance Committee or any other Board committees. The filing states his decision is not due to any disagreement with the company about its operations, policies or practices.

Key Details

• Date of notice: September 1, 2026; Form 8‑K filed September 2, 2026.
• Director: Brad Hively; will not stand for re‑election at the 2027 annual meeting.
• Immediate changes: Relieved of Vice Chairman title and all committee memberships, including the Compliance Committee.
• Company disclosure: Decision not linked to any disagreement with the company.

Why It Matters This is a governance change investors should note because it affects Board leadership and committee composition ahead of the 2027 annual meeting. The company did not report any dispute or operational issues tied to the departure, and Mr. Hively will continue as a director until the annual meeting, so there is time for the Board to consider replacements or committee reassignments before his eventual departure.